Kebirex 33® - for the treatment of intestinal dysbiosis and COVID-19 symptoms
€45,00
Unit price per Kebirex 33® is the multi-strain symbiotic food supplement for intestinal well-being in patients in the acute, post-acute and long COVID phase . Effective in the treatment of intestinal dysbiosis associated with SARS-CoV-2, contributing to the restoration of a healthy and balanced microbiota .
In association with standard therapy, it helps reduce symptoms and improve the clinical course of COVID-19, as well as providing support in the case of other viral infections that cause flu-like symptoms.
Recommended daily dose:
- 1 capsule per day , swallowed whole without chewing or opening.
- Case of 30 capsules
Warnings:
Keep out of reach of children under three years. Food supplements are not intended as a substitute for a varied, balanced diet and a healthy lifestyle. Do not exceed the recommended daily dose. Do not consume after the expiry date. The expiry date refers to the product in its intact packaging and stored correctly.
Nutritional Table
Components
Per capsule
-
Kebirah®
569 mg
-
of which Probiotics
219 mg
-
L. salivarius (SGL 03)
7.5 billion CFU
-
B. bifidum (SGB 02)
5 billion UFC
-
B short (SGB 01)
5 Bln UFC
-
L. Kefiri (SGL 13)
7.5 billion UFC
-
L. rhamnosus (SGL 06)
7.5 billion UFC
-
FOS
125 mg
-
GOS
125 mg
-
Calcium butyrate
50 mg
-
Quercetin
50 mg
- All orders in Italy are shipped via our partner courier GLS .
- Free shipping on orders over €39 - orders under this amount have a €4.50 fee.
- Orders are processed and shipped from Monday to Friday until 3:30 pm. Orders placed after this time will simply be processed the next working day.
- Returns accepted within 14 days of receiving the product, which must be intact and in the original packaging. Contact us at smm@ntpbiotech.com to start the process.
Estimated delivery between July 15 and July 16 if you order within .
€45,00
Unit price per
Gluten free
Lactose free
Science-backed effectiveness
Clinical study Spallanzani
In a randomized, placebo-controlled, double-blind clinical study¹ conducted at INMI Lazzaro Spallanzani , 50 patients diagnosed with COVID-19 were randomly assigned (27:23) to receive oral KEBIREX33° or placebo for 5 weeks.
The study aimed to evaluate the safety of KEBIREX33® and its effect on the composition of the intestinal microbiota, in terms of microbial richness and diversity, in addition to the clinical-pathological parameters in patients with acute and post-acute COVID-19. For this purpose, fecal samples were collected for microbiota analysis and blood samples for the evaluation of blood chemistry parameters at pre-established time intervals (TO, T14 and T28).
Six months after enrollment, patients were administered a questionnaire to assess the persistence of symptoms associated with long COVID (asthenia, headache, dysgeusia, ageusia, diarrhea, etc.).
Supplementation with KEBIREX33® prevented the reduction in lymphocyte count and hemoglobin levels typical of viral infections , promoting the maintenance of adequate fibrinogen levels up to T28 and significantly reducing procalcitonin, a marker of COVID-19 severity, at
T14, compared to the placebo group.
In vitro and in vivo study
Several studies highlight the role of the gut microbiota in modulating inflammation and immune response in patients with COVID-19.
B. breve and B. bifidum produce SCFAs, which strengthen epithelial defenses and reduce the risk of respiratory infections. In patients with COVID-19, especially in severe forms, intestinal dysbiosis reduces the levels of butyrate and the bacteria that produce it, compromising the intestinal barrier and promoting systemic inflammation. Supplementation with L. rhamnosus is able to modulate the intestinal microbiota, promoting the production of butyrate . ¹²
An in vivo study on mice¹³ demonstrated that L. kefiri SGL 13 reduces intestinal dysbiosis, favoring the reduction of proinflammatory bacteria and the enrichment of those producing SCFA. An in vitro study ¹⁴ showed that a supplement with L. salivarius SGL 03 has antiviral effects against SARS-CoV-2, modulating the immune response and preventing serious complications such as cytokine storm.
- Choosing a selection results in a full page refresh.
- Opens in a new window.